Skip to main content
BMJ Clinical Evidence logoLink to BMJ Clinical Evidence
. 2010 Jan 5;2010:0605.

Hypothyroidism (primary)

Birte Nygaard 1
PMCID: PMC2907600  PMID: 21726489

Abstract

Introduction

Hypothyroidism is six times more common in women, affecting up to 40/10,000 each year (compared with 6/10,000 men).

Methods and outcomes

We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for clinical (overt) hypothyroidism? What are the effects of treatments for subclinical hypothyroidism? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results

We found six systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions

In this systematic review, we present information relating to the effectiveness and safety of the following interventions: levothyroxine, and levothyroxine plus liothyronine.

Key Points

Primary hypothyroidism is defined as low levels of blood thyroid hormone due to destruction of the thyroid gland. This destruction is usually caused by autoimmunity, or an intervention such as surgery, radioiodine, or radiation.

  • It can be classified as clinical (overt), when diagnosed by characteristic features, raised levels of thyroid stimulating hormone (TSH), and reduced levels of T4, or subclinical, when serum TSH is raised, but serum T4 is normal and there are no symptoms of thyroid dysfunction.

  • Hypothyroidism is 6 times more common in women, affecting up to 40/10,000 each year (compared with 6/10,000 men).

There is consensus that levothyroxine is effective in treating clinical (overt) hypothyroidism, but evidence is sparse.

  • Treatment can lead to hyperthyroidism, reduction of bone mass in postmenopausal women, and increased risk of atrial fibrillation.

  • We found no evidence from RCTs that levothyroxine plus liothyronine improves symptoms more than levothyroxine alone.

We don't know how effective levothyroxine is in treating people with subclinical hypothyroidism, as trials have been too small to detect any clinically relevant improvements in outcomes.

About this condition

Definition

Hypothyroidism is characterised by low levels of blood thyroid hormone. Clinical (overt) hypothyroidism is diagnosed on the basis of characteristic clinical features, consisting of mental slowing, depression, dementia, weight gain, constipation, dry skin, hair loss, cold intolerance, hoarse voice, irregular menstruation, infertility, muscle stiffness and pain, bradycardia, hypercholesterolaemia, combined with a raised blood level of thyroid stimulating hormone (TSH) (serum TSH levels >12 mU/L), and a low-serum thyroxine (T4) level (serum T4 <60 nmol/L). Subclinical hypothyroidism is diagnosed when serum TSH is raised (serum TSH levels >4 mU/L) but serum T4 is normal, with minor or no symptoms or signs of thyroid dysfunction. Primary hypothyroidism occurs after destruction of the thyroid gland because of autoimmunity (the most common cause), or medical intervention such as surgery, radioiodine, and radiation. Secondary hypothyroidism occurs after pituitary or hypothalamic damage, and results in insufficient production of TSH. Secondary hypothyroidism is not covered in this review. Euthyroid sick syndrome is diagnosed when tri-iodothyronine (T3) levels are low, serum T4 is low, and TSH levels are normal or low. Euthyroid sick syndrome is not covered in this review.

Incidence/ Prevalence

Hypothyroidism is more common in women than in men (in the UK, female:male ratio of 6:1). One study (2779 people in the UK with a median age of 58 years) found that the incidence of clinical (overt) hypothyroidism was 40/10,000 women a year and 6/10,000 men a year. The prevalence was 9.3% in women and 1.3% in men. In areas with high iodine intake, the incidence of hypothyroidism can be higher than in areas with normal or low iodine intake. In Denmark, where there is moderate iodine insufficiency, the overall incidence of hypothyroidism is 1.4/10,000 a year, increasing to 8/10,000 a year in people over 70 years. The incidence of subclinical hypothyroidism increases with age. Up to 10% of women over the age of 60 years have subclinical hypothyroidism (evaluated from data from the Netherlands and USA).

Aetiology/ Risk factors

Primary thyroid gland failure can occur as a result of chronic autoimmune thyroiditis, radioactive iodine treatment, or thyroidectomy. Other causes include drug adverse effects (e.g., amiodarone and lithium), transient hypothyroidism due to silent thyroiditis, subacute thyroiditis, or postpartum thyroiditis.

Prognosis

In people with subclinical hypothyroidism, the risk of developing clinical (overt) hypothyroidism is described in the UK Whickham Survey (25 years' follow-up; for women: OR 8, 95% CI 3 to 20; for men: OR 44, 95% CI 19 to 104; if both a raised TSH and positive antithyroid antibodies were present; for women: OR 38, 95% CI 22 to 65; for men: OR 173, 95% CI 81 to 370). For women, the survey found an annual risk of 4.3% a year (if both raised serum TSH and antithyroid antibodies were present) and 2.6% a year (if raised serum TSH was present alone); the minimum number of people with raised TSH and antithyroid antibodies who would need treating to prevent this progression to clinical (overt) hypothyroidism in one person over 5 years is 5 to 8. Cardiovascular disease: A large cross-sectional study (25,862 people with serum TSH between 5.1 mU/L and 10.0 mU/L) found significantly higher mean total cholesterol concentrations in people who were hypothyroid compared with people who were euthyroid (5.8 mmol/L v 5.6 mmol/L). Another study (124 elderly women with subclinical hypothyroidism, 931 women who were euthyroid) found a significantly increased risk of MI in women with subclinical hypothyroidism (OR 2.3, 95% CI 1.3 to 4.0) and of aortic atherosclerosis (OR 1.7, 95% CI 1.1 to 2.6). Mental health: Subclinical hypothyroidism is associated with depression. People with subclinical hypothyroidism may have depression that is refractory to both antidepressant drugs and thyroid hormone alone. Memory impairment, hysteria, anxiety, somatic complaints, and depressive features without depression have been described in people with subclinical hypothyroidism.

Aims of intervention

To eliminate the symptoms of hypothyroidism and maximise quality of life.

Outcomes

Symptom severity; quality of life; cognitive function (evaluated by cognitive function tests, memory tests, reaction time, self-rating mood scales, and depression scores); cardiac function (evaluated by echocardiography); changes in body composition (measured by osteodensitometry or bioimpedance measurements); prevention of progression from subclinical to overt hypothyroidism; and adverse effects of treatments (bone mass, fracture rate, CVD [episodes of atrial fibrillation and ischaemic events]; development of hyperthyroidism).

Methods

Clinical Evidence search and appraisal September 2009. The following databases were used to identify studies for this systematic review: Medline 1966 to September 2009, Embase 1980 to September 2009, and The Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Clinical Trials, Issue 3, 2009. Additional searches were carried out using these websites: NHS Centre for Reviews and Dissemination (CRD) — for Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA), Turning Research into Practice (TRIP), and NICE. Abstracts of the studies retrieved from the initial search were assessed by an information specialist. Selected studies were then sent to the author for additional assessment, using predetermined criteria to identify relevant studies. Study design criteria for inclusion in this review were: published systematic reviews and RCTs in any language, at least single blinded, and containing >20 individuals of whom >80% were followed up. There was no minimum length of follow-up required to include studies. We excluded all studies described as "open", "open label", or not blinded unless blinding was impossible. We use a regular surveillance protocol to capture harms alerts from organisations such as the FDA and the MHRA, which are added to the reviews as required. To aid readability of the numerical data in our reviews, we round percentages to the nearest whole number. Readers should be aware of this when relating percentages to summary statistics such as relative risks (RRs) and odds ratios (ORs). We have performed a GRADE evaluation of the quality of evidence for interventions included in this review (see table). The categorisation of the quality of the evidence (high, moderate, low, or very low) reflects the quality of evidence available for our chosen outcomes in our defined populations of interest. These categorisations are not necessarily a reflection of the overall methodological quality of any individual study, because the Clinical Evidence population and outcome of choice may represent only a small subset of the total outcomes reported, and population included, in any individual trial. For further details of how we perform the GRADE evaluation and the scoring system we use, please see our website (www.clinicalevidence.com).

Table.

GRADE Evaluation of interventions for Hypothyroidism (primary).

Important outcomes Cardiac function, Changes in body composition, Cognitive function, Prevention of progression from subclinical to overt hypothyroidism, Quality of life, Symptom severity
Studies (Participants) Outcome Comparison Type of evidence Quality Consistency Directness Effect size GRADE Comment
What are the effects of treatments for clinical (overt) hypothyroidism?
at least 6 (at least 465) Symptom severity Levothyroxine (L-thyroxine) plus liothyronine versus L-thyroxine alone 4 0 0 –1 0 Moderate Directness point deducted for multiple/different regimens used
7 (532) Quality of life Levothyroxine (L-thyroxine) plus liothyronine versus L-thyroxine alone 4 0 0 –1 0 Moderate Directness point deducted for multiple/different regimens used
11 (at least 646) Cognitive function Levothyroxine (L-thyroxine) plus liothyronine versus L-thyroxine alone 4 0 0 –1 0 Moderate Directness point deducted for multiple/different regimens used
What are the effects of treatments for subclinical hypothyroidism?
at least 4 (at least 164) Symptom severity Levothyroxine replacement versus placebo or non-treatment 4 –2 0 0 0 Low Quality points deducted for sparse data and unclear outcome measures
2 (104) Cognitive function Levothyroxine replacement versus placebo or non-treatment 4 –2 0 0 0 Low Quality points deducted for sparse data and unclear outcome measures
2 (65) Quality of life Levothyroxine replacement versus placebo or non-treatment 4 –1 0 0 0 Moderate Quality point deducted for sparse data
1 (40) Cardiac function Levothyroxine replacement versus placebo or non-treatment 4 –1 0 0 0 Moderate Quality point deducted for sparse data

We initially allocate 4 points to evidence from RCTs, and 2 points to evidence from observational studies. To attain the final GRADE score for a given comparison, points are deducted or added from this initial score based on preset criteria relating to the categories of quality, directness, consistency, and effect size. Quality: based on issues affecting methodological rigour (e.g., incomplete reporting of results, quasi-randomisation, sparse data [<200 people in the analysis]). Consistency: based on similarity of results across studies. Directness: based on generalisability of population or outcomes. Effect size: based on magnitude of effect as measured by statistics such as relative risk, odds ratio, or hazard ratio.

Glossary

Low-quality evidence

Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Moderate-quality evidence

Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

T3

is used as an abbreviation for endogenous tri-iodothyronine in medical and biochemical reports.

T4

is used as an abbreviation for endogenous thyroxine in medical and biochemical reports.

Disclaimer

The information contained in this publication is intended for medical professionals. Categories presented in Clinical Evidence indicate a judgement about the strength of the evidence available to our contributors prior to publication and the relevant importance of benefit and harms. We rely on our contributors to confirm the accuracy of the information presented and to adhere to describe accepted practices. Readers should be aware that professionals in the field may have different opinions. Because of this and regular advances in medical research we strongly recommend that readers' independently verify specified treatments and drugs including manufacturers' guidance. Also, the categories do not indicate whether a particular treatment is generally appropriate or whether it is suitable for a particular individual. Ultimately it is the readers' responsibility to make their own professional judgements, so to appropriately advise and treat their patients. To the fullest extent permitted by law, BMJ Publishing Group Limited and its editors are not responsible for any losses, injury or damage caused to any person or property (including under contract, by negligence, products liability or otherwise) whether they be direct or indirect, special, incidental or consequential, resulting from the application of the information in this publication.

References

  • 1.Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorder in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 1995;43:55–68. [DOI] [PubMed] [Google Scholar]
  • 2.Laurberg P, Bülow Pedersen I, Pedersen KM, et al. Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. Thyroid 1999;9:33–38. [DOI] [PubMed] [Google Scholar]
  • 3.Canaris GJ, Manowitz NR, Mayor G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526–533. [DOI] [PubMed] [Google Scholar]
  • 4.Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000;132:270–278. [DOI] [PubMed] [Google Scholar]
  • 5.Haggerty JJ, Stern RA, Mason GA, et al. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry 1993;150:508–510. [DOI] [PubMed] [Google Scholar]
  • 6.Monzani F, Del Guerra P, Caraccio N, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment. Clin Invest 1993;71:367–371. [DOI] [PubMed] [Google Scholar]
  • 7.Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992;37:500–503. [DOI] [PubMed] [Google Scholar]
  • 8.Faber J, Galløe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350–356. Search date not reported. [DOI] [PubMed] [Google Scholar]
  • 9.Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249–1252. [DOI] [PubMed] [Google Scholar]
  • 10.Grozinsky-Glasberg S, Fraser A, Nahshoni E, et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006;91:2592–2599. [DOI] [PubMed] [Google Scholar]
  • 11.Joffe RT, Brimacombe M, Levitt AJ, et al. Treatment of clinical hypothyroidism with thyroxine and triiodothyronine: a literature review and metaanalysis. Psychosomatics 2007;48:379–384. [DOI] [PubMed] [Google Scholar]
  • 12.Villar HC, Saconato H, Valente O, et al. Thyroid hormone replacement for subclinical hypothyroidism. In: The Cochrane Library, Issue 3, 2009. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Monzani F, Bello VD, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind placebo-controlled study. J Clin Endocrinol Metab 2001;86:1110–1115. [DOI] [PubMed] [Google Scholar]
BMJ Clin Evid. 2010 Jan 5;2010:0605.

Levothyroxine (L-thyroxine) for clinical (overt) hypothyroidism

Summary

We found no direct information from RCTs about whether levothyroxine is better than no active treatment. There is consensus that treatment reduces symptoms.

Treating clinical (overt) hypothyroidism with thyroid hormone (levothyroxine) may induce hyperthyroidism and increase the risk of atrial fibrillation.

Benefits and harms

Levothyroxine (L-thyroxine) versus placebo:

We found no systematic review or RCTs comparing L-thyroxine versus placebo in people with clinical hypothyroidism, although there is consensus that treatment improves symptoms (see comment below). We found one longitudinal observational study, one systematic review (search date not reported), and one cohort study that reported on adverse effects of levothyroxine.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Fracture rate
1180 people Fracture rate 8.6 years (average)
with L-thyroxine
with control
Absolute results not reported

P value not reported
Reported as not significant
Not significant
Bone mass

Systematic review
441 premenopausal women, average age 40 years
13 RCTs in this analysis
Subgroup analysis
Bone mass 8.5 years
with L-thyroxine (164 micrograms/day)
with control
Absolute numbers not reported

Difference –2.7%
P value reported as not significant
Not significant

Systematic review
317 postmenopausal women, average age 61.2 years
13 RCTs in this analysis
Subgroup analysis
Bone mass 9.9 years
with L-thyroxine (171 micrograms/day)
with control
Absolute numbers not reported

Difference –9.0%
95% CI –2.4% to –15.7%
Effect size not calculated control
Atrial fibrillation

Cohort study
1637 people aged >60 years, serum TSH concentrations 0.1 mU/L or less Increased risk of atrial fibrillation (diagnosed by electrocardiogram) 10 years
28 per 1000 person-years with low serum TSH concentrations (0.1 mU/L or less)
11 per 1000 person-years with normal TSH values

P = 0.005
Effect size not calculated normal TSH values

Cohort study
1637 people aged >60 years, serum TSH concentrations 0.1 mU/L or less Atrial fibrillation event rate 10 years
13/61 (21%) with low serum TSH concentrations (0.1 mU/L or less)
133/1576 (8%) with normal TSH values

RR adjusted for other known risk factors 3.1
95% CI 1.7 to 5.5
Moderate effect size normal TSH values

Levothyroxine (L-thyroxine) versus L-thyroxine plus liothyronine:

See levothyroxine (L-thyroxine) plus liothyronine.

Further information on studies

None.

Comment

There is consensus that treatment with L-thyroxine improves symptoms. A placebo-controlled trial would be considered unethical. Over-treatment with L-thyroxine may cause hyperthyroidism.

Substantive changes

No new evidence

BMJ Clin Evid. 2010 Jan 5;2010:0605.

Levothyroxine (L-thyroxine) plus liothyronine for clinical (overt) hypothyroidism

Summary

We found no evidence from RCTs that levothyroxine plus liothyronine improves symptoms compared with levothyroxine alone.

Treating clinical (overt) hypothyroidism with thyroid hormone (levothyroxine) can induce hyperthyroidism and reduce bone mass in postmenopausal women, and can increase the risk of atrial fibrillation.

Benefits and harms

Levothyroxine (L-thyroxine) plus liothyronine versus placebo:

We found no systematic review or RCTs.

Levothyroxine (L-thyroxine) plus liothyronine versus L-thyroxine alone:

We found two systematic reviews, one with a search date of 2005. The second review had a later search date but included no further RCTs.

Symptom severity

Levothyroxine plus liothyronine compared with levothyroxine alone Levothyroxine plus liothyronine seems no more effective at reducing body pain and fatigue (moderate-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Symptom severity

Systematic review
465 people
4 RCTs in this analysis
Body pain
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute results not reported

SMD 0
95% CI –0.34 to +0.35
Not significant

Systematic review
173 people
6 RCTs in this analysis
Fatigue
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute results not reported

SMD –0.12
95% CI –0.33 to +0.09
Not significant

No data from the following reference on this outcome.

Quality of life

Levothyroxine plus liothyronine compared with levothyroxine alone Levothyroxine plus liothyronine seems no more effective at improving quality of life (moderate-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Quality of life

Systematic review
532 people
7 RCTs in this analysis
Quality of life
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute numbers not reported

SMD +0.03
95% CI –0.09 to +0.15
Not significant

No data from the following reference on this outcome.

Cognitive function

Levothyroxine plus liothyronine compared with levothyroxine alone Levothyroxine plus liothyronine seems no more effective at improving cognitive function, anxiety, and depression (moderate-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Cognitive function

Systematic review
646 people
11 RCTs in this analysis
Depression
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute numbers not reported

SMD +0.07
95% CI –0.20 to +0.34
Not significant

Systematic review
Number of people not reported
7 RCTs in this analysis
Anxiety
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute numbers not reported

SMD 0
95% CI –0.12 to +0.11
Not significant

Systematic review
386 people
5 RCTs in this analysis
Cognitive function (Symbol Digit Modalities Test)
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute numbers not reported

WMD +0.15
95% CI –0.79 to +1.08
Not significant

Systematic review
571 people
8 RCTs in this analysis
Cognitive function (Digit Span Sub-Test [forward sub-test])
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute numbers not reported

WMD –0.02
95% CI –0.25 to +0.22
Not significant

Systematic review
571 people
8 RCTs in this analysis
Cognitive function (Digit Span Sub-Test [backward sub-test])
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute numbers not reported

WMD –0.07
95% CI –0.30 to +0.15
Not significant

No data from the following reference on this outcome.

Cardiac function

No data from the following reference on this outcome.

Changes in body composition

No data from the following reference on this outcome.

Prevention of progression from subclinical to overt hypothyroidism

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

Systematic review
1216 people
11 RCTs in this analysis
Adverse effects
with L-thyroxine plus liothyronine (L-tri-iodothyronine)
with L-thyroxine alone
Absolute numbers not reported

RR 1.19
95% CI 0.63 to 2.24
Not significant

No data from the following reference on this outcome.

Further information on studies

The review pooled data. Seven included RCTs were crossover in design, and 4 included RCTs were parallel in design. The RCTs included in the review ranged in size from 13 to 697 people. The review found no significant difference between groups in thyroid function tests or serum lipid levels. The review concluded that monotherapy with L-thyroxine should remain the standard treatment for hypothyroidism. The RCTs included used widely different combinations/regimens in the L-thyroxine plus liothyronine arms of the trials.

Comment

None.

Substantive changes

Levothyroxine (L-thyroxine) plus liothyronine for clinical (overt) hypothyroidism One systematic review added comparing L-thyroxine alone versus a combination of L-thyroxine plus liothyronine (L-tri-iodothyronine) in people with primary hypothyroidism. The review added no further data than already included and also found no difference between groups in psychiatric symptoms. Categorisation unchanged (Unlikely to be beneficial).

BMJ Clin Evid. 2010 Jan 5;2010:0605.

Levothyroxine (L-thyroxine) for subclinical hypothyroidism

Summary

We don't know how effective levothyroxine is in treating people with subclinical hypothyroidism, as trials have been too small to detect any clinically relevant improvements in outcomes.

Treating subclinical hypothyroidism with thyroid hormone can induce hyperthyroidism and reduce bone mass in postmenopausal women, and can increase the risk of atrial fibrillation.

Benefits and harms

Levothyroxine replacement versus placebo or non-treatment:

We found one systematic review (search date 2006) comparing levothyroxine replacement versus placebo (11 RCTs) or no treatment (1 RCT) in adults with subclinical hypothyroidism. RCTs included in the review had a minimum follow-up of 1 month. We found one additional RCT that assessed the effects of L-thyroxine on cardiac function.

Symptom severity

Compared with placebo or no treatment We don't know whether levothyroxine is more effective at reducing symptom severity in people with subclinical hypothyroidism (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Symptom severity

Systematic review
24 people
Data from 1 RCT
Improved symptoms
with levothyroxine
with placebo
Absolute numbers not reported

RR 2.5
95% CI 0.80 to 7.83
Not significant

Systematic review
155 people
4 RCTs in this analysis
Symptom scores
with levothyroxine
with placebo
Absolute numbers not reported

SMD –0.30
95% CI –0.62 to +0.02
P = 0.48
Not significant

Systematic review
164 people
3 RCTs in this analysis
Change in symptom scores
with levothyroxine
with placebo
Absolute numbers not reported

SMD –0.24
95% CI –0.54 to +0.07
P = 0.70
Not significant

No data from the following reference on this outcome.

Cognitive function

Compared with placebo or no treatment Levothyroxine may be more effective at improving cognitive function in people with subclinical hypothyroidism, but we don't know whether it is more effective at improving depression (low-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Cognitive function

Systematic review
36 people
Data from 1 RCT
Cognitive function
with levothyroxine
with placebo
Absolute numbers not reported

SMD 2.40
95% CI 0.30 to 4.50
Effect size not calculated levothyroxine

Systematic review
68 people
Data from 1 RCT
Emotional function tests of depressed mood
with levothyroxine
with placebo
Absolute numbers not reported

SMD +0.06
95% CI –0.41 to +0.54
P = 0.81
Not significant

No data from the following reference on this outcome.

Quality of life

Compared with placebo or no treatment Levothyroxine seems no more effective at improving quality of life or health-related quality of life in people with subclinical hypothyroidism (moderate-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Quality of life

Systematic review
34 people
Data from 1 RCT
Proportion of people improved on general health questionnaire
12/20 (60%) with levothyroxine
11/14 (78%) with placebo

RR 0.76
95% CI 0.49 to 1.20
P = 0.24
Not significant

Systematic review
31 people
Data from 1 RCT
Changes in health-related quality of life
with levothyroxine
with placebo
Absolute numbers not reported

SMD +0.08
95% CI –0.62 to +0.79
P = 0.98
Not significant

No data from the following reference on this outcome.

Cardiac function

Compared with placebo Levothyroxine seems more effective at improving left ventricular function at 6 months (moderate-quality evidence).

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Cardiac function

RCT
40 people with increased TSH, and normal T4 and T3 for least 1 year Left ventricular function (increased isovolumic relaxation time) 6 months
with L-thyroxine (50 micrograms/day)
with placebo
Absolute numbers not reported

P <0.03
Effect size not calculated L-thyroxine

RCT
40 people with increased TSH, and normal T4 and T3 for least 1 year Left ventricular function (peak A) 6 months
with L-thyroxine (50 micrograms/day)
with placebo
Absolute numbers not reported

P <0.05
Effect size not calculated L-thyroxine

RCT
40 people with increased TSH, and normal T4 and T3 for least 1 year Left ventricular function (pre-ejection/ejection time ratio) 6 months
with L-thyroxine (50 micrograms/day)
with placebo
Absolute numbers not reported

P <0.03
Effect size not calculated L-thyroxine

RCT
40 people with increased TSH, and normal T4 and T3 for least 1 year Left ventricular function (cyclic variation index) 6 months
with L-thyroxine (50 micrograms/day)
with placebo
Absolute numbers not reported

P <0.05
Effect size not calculated L-thyroxine

No data from the following reference on this outcome.

Changes in body composition

No data from the following reference on this outcome.

Prevention of progression from subclinical to overt hypothyroidism

No data from the following reference on this outcome.

Adverse effects

Ref (type) Population Outcome, Interventions Results and statistical analysis Effect size Favours
Adverse effects

Systematic review
138 people
4 RCTs in this analysis
Adverse effects
with levothyroxine
with placebo
Absolute numbers not reported

The RCTs that reported on adverse effects found no significant differences between groups
No further data reported
Not significant

No data from the following reference on this outcome.

Further information on studies

None.

Comment

None.

Substantive changes

Levothyroxine (L-thyroxine) for subclinical hypothyroidism One systematic review added comparing thyroid hormone replacement versus placebo or no treatment. The review found that hormone replacement improved general symptoms and cognitive function compared with placebo or no treatment, but found no difference between groups for quality of life or health-related quality of life. Categorisation unchanged (Unknown effectiveness).


Articles from BMJ Clinical Evidence are provided here courtesy of BMJ Publishing Group

RESOURCES